BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29569486)

  • 1. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicity.
    Gutierrez-Camino A; Umerez M; Santos B; Martin-Guerrero I; García de Andoin N; Sastre A; Navajas A; Astigarraga I; Garcia-Orad A
    Epigenomics; 2018 Apr; 10(4):409-417. PubMed ID: 29569486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.
    Gutierrez-Camino A; Oosterom N; den Hoed MAH; Lopez-Lopez E; Martin-Guerrero I; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; Heil SG; García-Orad A; van den Heuvel-Eibrink MM
    Pharmacogenet Genomics; 2017 Aug; 27(8):303-306. PubMed ID: 28628559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
    Iparraguirre L; Gutierrez-Camino A; Umerez M; Martin-Guerrero I; Astigarraga I; Navajas A; Sastre A; Garcia de Andoin N; Garcia-Orad A
    Pharmacogenet Genomics; 2016 Nov; 26(11):517-525. PubMed ID: 27649261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment.
    Gutierrez-Camino Á; Umerez M; Lopez-Lopez E; Santos-Zorrozua B; Martin-Guerrero I; de Andoin NG; Ana S; Navajas A; Astigarraga I; Garcia-Orad A
    Pharmacogenomics; 2018 Dec; 19(18):1403-1412. PubMed ID: 30479191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia.
    Hagag AA; AbdElaal AM; Elfaragy MS; Hassan SM; Elzamarany EA
    Infect Disord Drug Targets; 2015; 15(1):64-71. PubMed ID: 25809628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia.
    Pakakasama S; Kanchanakamhaeng K; Kajanachumpol S; Udomsubpayakul U; Sirachainan N; Thithapandha A; Hongeng S
    Ann Hematol; 2007 Aug; 86(8):609-11. PubMed ID: 17323057
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.
    Umerez M; Garcia-Obregon S; Martin-Guerrero I; Astigarraga I; Gutierrez-Camino A; Garcia-Orad A
    Pharmacogenomics; 2018 Mar; 19(4):361-373. PubMed ID: 29469670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic factors on long-term treatment related neurocognitive complications, and on anxiety and depression in survivors of childhood acute lymphoblastic leukemia: The Petale study.
    Petrykey K; Lippé S; Robaey P; Sultan S; Laniel J; Drouin S; Bertout L; Beaulieu P; St-Onge P; Boulet-Craig A; Rezgui A; Yasui Y; Sapkota Y; Krull KR; Hudson MM; Laverdière C; Sinnett D; Krajinovic M
    PLoS One; 2019; 14(6):e0217314. PubMed ID: 31181069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
    Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis.
    Vagace JM; Caceres-Marzal C; Jimenez M; Casado MS; de Murillo SG; Gervasini G
    Am J Hematol; 2011 Jan; 86(1):98-101. PubMed ID: 21064136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility.
    Gutierrez-Camino A; Lopez-Lopez E; Martin-Guerrero I; Piñan MA; Garcia-Miguel P; Sanchez-Toledo J; Carbone Bañeres A; Uriz J; Navajas A; Garcia-Orad A
    Pediatr Res; 2014 Jun; 75(6):767-73. PubMed ID: 24618566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
    Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with ALL.
    Zaruma-Torres F; Lares-Asseff I; Reyes-Espinoza A; Loera-Castañeda V; Chairez-Hernández I; Sosa-Macías M; Galaviz-Hernández C; Almanza-Reyes H
    Drug Metab Pers Ther; 2015 Sep; 30(3):195-201. PubMed ID: 26353179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.
    Abdelaziz DH; Elhosseiny NM; Khaleel SA; Sabry NA; Attia AS; El-Sayed MH
    Pediatr Blood Cancer; 2016 Sep; 63(9):1539-45. PubMed ID: 27163515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.